- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00909532
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation (STRIVE)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-770 in Subjects With Cystic Fibrosis and the G551D Mutation
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This was a phase 3 study in subjects with cystic fibrosis (CF) age 12 years and older who have a G551D-CFTR mutation and percent predicted forced expiratory volumn in 1 second (FEV1) between 40% and 90%.
Based on in vitro studies and pharmacologic, pharmacokinetic (PK), and safety profiles, ivacaftor was selected for clinical development as a possible treatment for patients with CF. Patients with the G551D mutation were the targeted population for this study because ivacaftor is a potentiator of the gating function of the CFTR protein, and the most prevalent mutation with a gating defect in CF is the G551D mutation.
This study was designed to further evaluate the efficacy of ivacaftor in subjects with CF who have a G551D-CFTR gene mutation and to evaluate safety in this population over a longer period than previously studied.
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Erlangen, Allemagne, 91054
- Kinder- und Jugendklinik Universitätsklinikum Erlangen
-
Jena, Allemagne, 07740
- Mukoviszidose-Zentrum am Klinikum der Friedrich-Schiller-Universität Jena, Klinik für Kinder- und Jugendmedizin
-
Munich, Allemagne, 80337
- Klinikum der LMU München, Dr. von Haunersches Kinderspital (CHA)
-
Wurzburg, Allemagne, 97080
- Universitäts-Kinderklinik Würzburg
-
-
-
-
New South Wales
-
Westmead, New South Wales, Australie, 2145
- The Children's Hospital Westmead
-
-
Queensland
-
Chermside, Queensland, Australie, 4032
- The Prince Charles Hospital
-
Herston, Queensland, Australie, 4026
- Royal Children's Hospital Brisbane
-
South Brisbane, Queensland, Australie, 4101
- Mater Adult Hospital
-
-
Victoria
-
Parkville, Victoria, Australie, 3052
- Royal Children's Hospital Melbourne
-
-
Western Australia
-
Nedlands, Western Australia, Australie, 6009
- Lung Institute of Western Australia
-
Subiaco, Western Australia, Australie, 6008
- Princess Margaret Hospital for Children
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 3A7
- Queen Elizabeth II Health Sciences Centre
-
-
Ontario
-
Toronto, Ontario, Canada, M5B 1W8
- St. Michael's Hospital
-
Toronto, Ontario, Canada, M5G 1X8
- CF Center, Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- Montreal Children's Hospital - MUHC
-
-
-
-
-
Paris, France, 75014
- Hôpital Cochin
-
Paris, France, 75015
- Hopital Necker
-
Roscoff, France, 29684
- Centre de Perharidy
-
-
-
-
-
Cork, Irlande
- Cork University Hospital
-
Dublin, Irlande, 9
- Beaumont Hospital
-
Dublin, Irlande, 4
- St. Vincent's University Hospital
-
Dublin, Irlande, 12
- Our Lady's Children's Hospital
-
Dublin, Irlande, 24
- The National Children's Hospital
-
-
-
-
-
London, Royaume-Uni, SW3 6LR
- Imperial College London
-
-
Northern Ireland
-
Belfast, Northern Ireland, Royaume-Uni, BT9 7AB
- Belfast City Hospital
-
-
-
-
-
Prague, République tchèque, 15006
- FN Motol
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35233-1711
- University of Alabama
-
-
California
-
Oakland, California, États-Unis, 94611
- Kaiser Permanente Medical Care Program
-
Palo Alto, California, États-Unis, 94304
- Cystic Fibrosis Research Office, Stanford University
-
San Diego, California, États-Unis, 92123-5070
- Rady Children's Hospital
-
-
Colorado
-
Denver, Colorado, États-Unis, 80206
- National Jewish Medical and Research Center
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Emory Cystic Fibrosis Center
-
-
Idaho
-
Boise, Idaho, États-Unis, 83712
- St. Luke's CF Clinic
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60614
- Children's Memorial Hospital
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Indiana University
-
-
Iowa
-
Iowa City, Iowa, États-Unis, 52242
- University of Iowa
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21205
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, États-Unis, 02115
- Children's Hospital Boston
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- University of Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55455
- Pulmonary, Allergy & Critical Care Medicine, University of Minnesota
-
-
Missouri
-
Kansas City, Missouri, États-Unis, 64108
- The Children's Mercy Hospital
-
St. Louis, Missouri, États-Unis, 63110
- Washington University
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68198-5300
- Adult Pulmonary/ CF, University of Nebraska Medical Center
-
-
New Jersey
-
Long Branch, New Jersey, États-Unis, 07740
- Monmouth Medical Center
-
-
New York
-
Buffalo, New York, États-Unis, 14222
- Women and Children's Hospital of Buffalo
-
New Hyde Park, New York, États-Unis, 11042
- Long Island Jewish Medical Center
-
Syracuse, New York, États-Unis, 13210
- SUNY Upstate Medical University
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27599
- University of North Carolina at Chapel Hill
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, États-Unis, 44106
- Pediatric & Pulmonary Division, Rainbow Babies/Case Western
-
Columbus, Ohio, États-Unis, 43205
- Nationwide Children's Hospital
-
Toledo, Ohio, États-Unis, 43606
- Toledo Children's Hospital
-
-
Oregon
-
Portland, Oregon, États-Unis, 97239-3098
- Oregon Health & Sciences University
-
-
Pennsylvania
-
Hershey, Pennsylvania, États-Unis, 17033
- Hershey Medical Center
-
Philadelphia, Pennsylvania, États-Unis, 19104
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, États-Unis, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Tennessee
-
Knoxville, Tennessee, États-Unis, 37916
- East Tennessee Children's Hospital
-
Nashville, Tennessee, États-Unis, 37232-5735
- Vanderbilt University Medical Center
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84132
- University of Utah
-
-
Virginia
-
Charlottesville, Virginia, États-Unis, 22908
- University of Virginia
-
-
Washington
-
Seattle, Washington, États-Unis, 98105
- Seattle Children's Hospital
-
Seattle, Washington, États-Unis, 98195-6522
- Division of Pulmonary and CCM, University of Washington
-
-
West Virginia
-
Morgantown, West Virginia, États-Unis, 26506
- West Virginia University
-
-
Wisconsin
-
Milwaukee, Wisconsin, États-Unis, 53226
- Medical College of Wisconsin
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Confirmed diagnosis of cystic fibrosis (CF) and G551D mutation in at least 1 allele
- Forced expiratory volume in 1 second (FEV1) of 40% to 90% (inclusive) of predicted normal for age, gender, and height at Screening.
- No clinically significant abnormalities that would have interfered with the study assessments, as judged by the investigator
- Willing to use highly effective birth control methods during the study
Exclusion Criteria:
- History of any illness or condition that might confound the results of the study or pose an additional risk in administering study drug to the subject
- Acute respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 4 weeks of Day 1 of the study
- History of alcohol, medication or illicit drug abuse within one year prior to Day 1
- Abnormal liver function ≥ 3x the upper limit of normal
- Abnormal renal function at Screening
- History of solid organ or hematological transplantation
- Pregnant, planning a pregnancy, breast-feeding, or unwilling to follow contraception requirements
- Ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within 30 days prior to Screening
- Use of inhaled hypertonic saline treatment
- Concomitant use of any inhibitors or inducers of cytochrome P450 3A4 (CYP 3A4)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Comparateur placebo: Placebo
Sujets ayant reçu un placebo toutes les 12 heures (q12h) pendant 48 semaines maximum.
|
Comprimé administré par voie orale q12h pendant 48 semaines maximum
|
Expérimental: 150 mg Ivacaftor q12h
Sujets ayant reçu 150 mg d'ivacaftor toutes les 12 heures pendant 48 semaines maximum.
|
150-mg tablets given orally q12h for up to 48 weeks
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24
Délai: baseline through 24 weeks
|
Spirometry (as measured by FEV1) is a standardized assessment to evaluate lung function that is the most widely used endpoint in cystic fibrosis studies.
|
baseline through 24 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Changement absolu de la concentration de chlorure dans la sueur par rapport à la ligne de base jusqu'à la semaine 24 et la semaine 48
Délai: ligne de base jusqu'à 24 semaines et 48 semaines
|
Le test de chlorure de sueur (iontophorèse quantitative de la pilocarpine) est un outil de diagnostic standard pour la mucoviscidose (FK), servant d'indicateur de l'activité du régulateur de la conductance transmembranaire de la mucoviscidose (CFTR).
|
ligne de base jusqu'à 24 semaines et 48 semaines
|
Changement absolu du poids par rapport au départ à la semaine 24 et à la semaine 48
Délai: ligne de base à 24 semaines et 48 semaines
|
Comme la malnutrition est courante chez les patients atteints de mucoviscidose (FK) en raison de l'augmentation des dépenses énergétiques due aux maladies pulmonaires et à la malabsorption des graisses, le poids corporel est une mesure clinique importante de l'état nutritionnel.
|
ligne de base à 24 semaines et 48 semaines
|
Absolute Mean Change From Baseline in Percent Predicted FEV1 Through Week 48
Délai: baseline through 48 weeks
|
Spirometry (as measured by FEV1) is a standardized assessment to evaluate lung function that is the most widely used endpoint in cystic fibrosis studies.
|
baseline through 48 weeks
|
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Score Through Week 24 and Week 48 (Respiratory Domain Score, Pooled)
Délai: baseline through 24 weeks and 48 weeks
|
The CFQ-R is a health-related quality of life measure for subjects with cystic fibrosis.
Each domain is scored from 0 (worst) to 100 (best).
A difference of at least 4 points in the respiratory domain score of the CFQ-R is considered a minimal clinically important difference (MCID).
|
baseline through 24 weeks and 48 weeks
|
Time-to-first Pulmonary Exacerbation Through Week 24 and Week 48
Délai: baseline through 24 weeks and 48 weeks
|
Pulmonary exacerbation was defined as a change in antibiotic therapy (intravenous, inhaled, or oral) for any 4 or more of signs/symptoms such as change in sputum; new or increased hemoptysis; increased cough or dyspnea; malaise, fatigue, or lethargy; temperature above 38 degrees C; anorexia or weight loss; sinus pain/tenderness and discharge; change in physical examination of the chest; decreased pulmonary function by 10%; and radiographic changes indicative of pulmonary infection.
|
baseline through 24 weeks and 48 weeks
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Bonnie W. Ramsey, MD, Children's Hospital and Regional Medical Center, Seattle, Washington, USA
- Chercheur principal: Stuart Elborn, MD, Respiratory Medicine Group, Queen's University of Belfast, Belfast, Northern Ireland, UK
Publications et liens utiles
Publications générales
- Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordonez C, Elborn JS; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011 Nov 3;365(18):1663-72. doi: 10.1056/NEJMoa1105185.
- Flume PA, Wainwright CE, Elizabeth Tullis D, Rodriguez S, Niknian M, Higgins M, Davies JC, Wagener JS. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. J Cyst Fibros. 2018 Jan;17(1):83-88. doi: 10.1016/j.jcf.2017.06.002. Epub 2017 Jun 24.
- Solem CT, Vera-Llonch M, Liu S, Botteman M, Castiglione B. Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis. Health Qual Life Outcomes. 2016 Apr 21;14:63. doi: 10.1186/s12955-016-0465-z.
- Quittner A, Suthoff E, Rendas-Baum R, Bayliss MS, Sermet-Gaudelus I, Castiglione B, Vera-Llonch M. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial. Health Qual Life Outcomes. 2015 Jul 2;13:93. doi: 10.1186/s12955-015-0293-6.
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du système digestif
- Processus pathologiques
- Maladies des voies respiratoires
- Maladies pulmonaires
- Nourrisson, nouveau-né, maladies
- Maladies génétiques, innées
- Maladies pancréatiques
- Fibrose
- Fibrose kystique
- Mécanismes moléculaires de l'action pharmacologique
- Modulateurs de transport membranaire
- Agonistes des canaux chlorure
- Ivacaftor
Autres numéros d'identification d'étude
- VX08-770-102
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Placebo
-
SamA Pharmaceutical Co., LtdInconnueBronchite aiguë | Infection aiguë des voies respiratoires supérieuresCorée, République de
-
Heptares Therapeutics LimitedComplétéPharmacocinétique | Des problèmes de sécuritéRoyaume-Uni
-
National Institute on Drug Abuse (NIDA)ComplétéConsommation de cannabisÉtats-Unis
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyComplétéSujets masculins atteints de diabète de type II (T2DM)Allemagne
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingComplétéMaladie de ParkinsonChine
-
ItalfarmacoComplétéDystrophie musculaire de BeckerPays-Bas, Italie
-
West Penn Allegheny Health SystemComplétéAsthme | Rhinite allergiqueÉtats-Unis
-
Guangdong Zhongsheng Pharmaceutical Co., Ltd.Complété
-
Regado Biosciences, Inc.ComplétéVolontaire en bonne santéÉtats-Unis